Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 17/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195553 | 1.00 | MAP4K4 (0.53) | MAP4K4HRH4HRH3HDAC1SUV39H2 | |
| SCHEMBL3209109 | 0.99 | MAP4K4 (0.52) | MAP4K4HRH4HRH3HDAC1SUV39H2 | |
| SCHEMBL3998971 | 0.85 | HRH4 (0.59) | HRH4HRH3 | |
| SCHEMBL3996125 | 0.85 | HRH4 (0.59) | HRH4HRH3 | |
| SCHEMBL3195770 | 0.84 | MAP4K4 (0.52) | MAP4K4HRH4HDAC1SUV39H2 | |
| SCHEMBL3197606 | 0.84 | HRH4 (0.61) | MAP4K4HRH4HRH3 | |
| SCHEMBL3211110 | 0.82 | HRH4 (0.54) | HRH4HRH3 | |
| SCHEMBL3190194 | 0.80 | HRH4 (0.61) | HRH4HRH3 | |
| SCHEMBL3203004 | 0.79 | SMARCA2 (0.49) | HRH4HRH3 | |
| SCHEMBL3197458 | 0.79 | SMARCA2 (0.49) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | MAP4K4 2924/4885HRH4 1/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.